Table 1. Demographic and serological baseline characteristics.
| Full dose (n = 291) | 1/5 dose (n = 224)* | 1/10 dose (n = 235)* | ||
| Age (years) | Median (IQR) | 9.1 (5.1–13.1) | 9.1 (5.1–13.1) | 9.1 (5.1–14.1) |
| Sex | Ratio (M/F) | 0.89 (137/154) | 1.06 (115/109) | 0.90 (111/124) |
| Weight (kg) | Median (IQR) | 25 (16–37) | 25 (17–37) | 25 (17–39) |
| Height (cm) | Median (IQR) | 128.0 (107–146.5) | 127.1 (110–146.5) | 129.8 (108.5–149.4) |
| SBA A titers | GMT (GSD) | 41.6 (21.6) | 58.7 (20.9) | 48.8 (21.0) |
| GMC IgG µg/mL ELISA A | GMC (GSD) | 2.6 (2.4) | 2.8 (2.3) | 2.4 (2.4) |
| SBA W135 titers | GMT (GSD) | 7.1 (10.0) | 6.0 (8.6) | 7.1 (10.1) |
| GMC IgG µg/mL ELISA W135 | GMC (GSD) | 2.7 (2.5) | 2.9 (2.4) | 2.9 (2.3) |
| SBA C titers | GMT (GSD) | 2.7 (3.5) | 2.8 (3.9) | 3.5 (5.3) |
| GMC IgG µg/mL ELISA C | GMC (GSD) | 0.9 (2.4) | 1.0 (2.4) | 1.0 (2.3) |
| SBA Y titers | GMT (GSD) | 2.2 (1.9) | 2.7 (3.8) | 2.2 (2.0) |
| GMC IgG µg/mL ELISA Y | GMC (GSD) | 2.9 (2.4) | 3.1 (2.4) | 3.1 (2.3) |
*: One patient randomized in the 1/5-dose group received 1/10 of the dose.
GSD: Geometric Standard Deviation.